Posted 2/26/2024, 10:25:00 PM
Global Axial Spondyloarthritis Treatment Market to Reach $8.79 Billion by 2030, Driven by Increasing Demand and Growing Prevalence
- Global axial spondyloarthritis market to reach $8.79 billion by 2030, growing at a 7.4% CAGR
- Market growth driven by increasing prevalence and demand for treatment
- Covers ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
- Profiles of key companies like Abbott, AbbVie, Amgen, Eli Lilly, Novartis, Pfizer
- Segmentation by type, drug class, end user (hospitals, clinics, research institutes, rehab centers)